Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study

Table 4 Frequencies of pituitary tumor according to antipsychotic treatment

	Clozapine	Risperidone	Olanzapine	Quetiapine	Ziprasidone	Haloperidol	Perphenazine	Other typicals
Number of treatment episodes	2,039	63,878	56,138	36,857	7,183	10,743	2,956	18,132
Pituitary tumor (all types), %:
Unadjusted*	0.25	0.26	0.13	0.13	0.18	0.15	0.03	0.24
Adjusted for antipsychotic treatment duration†	0.19	0.30	0.16	0.16	0.30	0.18	0.04	0.30

*Because of rounding, these percentages may differ from the sum of percentages in Table 1.
† Unadjusted percentages were raised or lowered to reflect 12-month treatment duration.

ISSN: 1744-859X